Dr. Osborn has over 25 years of drug development experience in the areas of clinical pharmacology and pharmacokinetics. She has focused primarily oncology and anti-infectives. 在加入 Certara 之前，她是美国 FDA 临床药理学办公室 CDER 癌症药理学部门的评审员，参与 Project Optimus 下多剂量依据递交的评估工作。Prior to working in the FDA, she was a clinical pharmacologist in the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institute of Health (NIH). There, projects were focused on therapeutics and vaccines in the infectious disease area. She worked on design and support of phase 1 trials, bioanalytical assay development and validation, and projects using the “Animal Rule” to support development of countermeasures in situations where clinical trials were not ethical or feasible. Dr. Osborn has held roles supporting both clinical and nonclinical pharmacology drug development for large molecules in biotechnology companies including Human Genome Sciences and CoGenesys. She is particularly interested in early phase drug development, including dose selection and justification strategies to speed development of therapeutics.

Dr. Osborn is holds a Ph.D. in Pharmacology from The George Washington University and is based in the Washington DC metropolitan area.